Description

Velimogene Aliplasmid is a specialized plasmid DNA construct designed for advanced gene therapy and genetic research applications. This product is critical for delivering therapeutic genes with high efficiency and specificity, enabling breakthroughs in the treatment of genetic disorders and oncology. It is an essential reagent for biopharmaceutical companies, contract research organizations (CROs), and academic institutions engaged in cell and gene therapy development, vaccine research, and molecular biology.

Application

• Gene Therapy Development: Serves as a non-viral vector for the delivery of therapeutic genes in preclinical and clinical research for monogenic diseases and cancer.
• DNA Vaccine Production: Used as the antigen-encoding plasmid in the development and manufacturing of novel DNA-based vaccines.
• Cell Engineering: Essential for the transfection and genetic modification of cell lines, including T-cells for CAR-T therapy and stem cells for regenerative medicine.
• Biomanufacturing: Acts as a critical starting material in the GMP-compliant production of viral vectors (e.g., AAV, Lentivirus) for advanced therapy medicinal products (ATMPs).
• Functional Genomics: Utilized in research for gene function analysis, overexpression studies, and the creation of stable cell lines.
• Diagnostic Reagent Development: Employed as a control or standard in the development of molecular diagnostic assays and kits.

Basic Information

Product Name	Velimogene Aliplasmid
CAS No.	296251-72-4
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	pVelimogene; Aliplasmid Velimogene; Gene Therapy Plasmid Velimogene; Plasmid DNA 296251-72-4; Therapeutic Plasmid Construct; pDNA Velimogene; Recombinant Plasmid Velimogene; Non-viral Vector 296251-72-4
EINECS	Contact for details

Quality Control

Our Velimogene Aliplasmid is manufactured under stringent quality systems. Each batch is subjected to a comprehensive panel of analytical tests to ensure identity, purity, potency, and sterility, meeting the exacting standards for pharmaceutical-grade plasmid DNA. Certificates of Analysis (COA) detailing specifications for supercoiled content, endotoxin levels, bioburden, and absence of host genomic DNA are provided. Production can be aligned with cGMP guidelines for clinical-stage material upon request.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store frozen at -20°C ± 5°C. Avoid repeated freeze-thaw cycles. Store under inert atmosphere if specified. Keep container dry and in a well-ventilated place.

Specification

Item	Specification
Appearance	White to off-white pellet or clear solution
Identification (Sequencing)	Conforms to reference sequence
Purity (A260/A280 Ratio)	1.80 - 2.00
Supercoiled Plasmid Content	≥ 90% (by HPLC or CE)
Assay (Concentration)	As per COA (Spectrophotometry)
Endotoxin	< 10 EU/mg plasmid
Bioburden	Meets specified limits
Sterility (where applicable)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.